ACE2 News and Research

RSS

Delta- and Omicron BA.1-variant specificity of B cell repertoires established by an initial Wuhan strain infection

Researchers performed an unbiased evaluation of the early memory B cell repertoire specific for the Omicron and Delta variants of SARS-CoV-2.

12 May 2022

Imprinted antibody responses towards SARS-CoV-2 Omicron subvariants

A new study analyzed the imprinted antibody responses towards the SARS-CoV-2 Omicron subvariants.

12 May 2022

SARS-CoV-2 Omicron escapes immune response due to high ACE2 affinity and low antibody specificity

In a recent study published in the journal Vaccines, researchers revealed how severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron evades neutralizing antibodies (nAbs).

12 May 2022

Antifungal agent Bifonazole as an antiviral against SARS-CoV-2

In a recent study published in the journal Molecular Therapy, researchers identified Bifonazole, an imidazole-based antifungal agent, to have potent activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using high-throughput screening of small molecules.

12 May 2022

Discovery of host co-factors necessary for SARS-CoV2 infection

A new study published in the journal EMBO Reports has reported on the shedding of two proteases, namely, ADAM10 and ADAM17, which aids in S protein-dependent molecular events.

11 May 2022

COVID-19-induced non-cell-autonomous anosmia

Researchers reported that SARS-CoV-2-induced anosmia was based on non-cell-independent processes.

11 May 2022

Decoy ACE2 nanoparticles block the entry of SARS-CoV-2 into cells

In a recent study posted to the bioRxiv* preprint server, researchers reported that nanoparticles could prevent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) cell entry.

10 May 2022

Evasion of COVID-19 vaccine-medicated mucosal immunity by SARS-CoV-2 Omicron

Researchers depicted the evasion of the SARS-CoV-2 Omicron variant to mucosal immunity in SARS-CoV-2 vaccine recipients.

10 May 2022

Research highlight reports on the observed differences in transmissibility and pathogenicity of Omicron vs. earlier variants of SARS-CoV-2

A new paper published in Signal Transduction and Targeted Therapy reports the observed differences in transmissibility and pathogenicity of Omicron vs. earlier variants of SARS-CoV-2.

10 May 2022

mRNA boosters enhance neutralization of SARS-CoV-2 BA.1, BA.2 and BA.3

A study recently published in the journal Cell Host & Microbe has described that all three sublineages of the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit similar host cell entry efficiency and are neutralized equally by antibodies generated in response to coronavirus disease 2019 (COVID-19) booster vaccination

10 May 2022

Deoxyribonucleic acid nanostructure sensor found to rapidly detect and inhibit SARS-CoV-2

Researchers reported on a three-layer designer deoxyribonucleic acid (DNA) nanostructure (DDN) strategy-based sensor designed by them for rapid and accurate SARS-CoV-2 detection and inhibition.

9 May 2022

Differences in COVID-19 outcomes related to sex

Researchers looked at gender variations in COVID-19 outcomes such as hospitalization, ICU admission, mortality, and heart damage.

9 May 2022

Study reveals immune responses to SARS-CoV-2 peptides in COVID-19 convalescent patients

A new study aimed to demonstrate the reactivity of COVID-19 serum obtained from patients in Tatarstan, Russia with S and N peptides that were previously identified as immunogenic.

9 May 2022

Infection with SARS-CoV-2 results in antibodies against common colds

A study published in the journal Science Advances uses electron microscopy-based polyclonal epitope mapping (EMPEM) methodology to elucidate the spike epitopes of β-HCoV targeted by preexisting serum antibodies and compares them to the epitopes targeted by antibodies elicited by SARS-CoV-2 infection using electron microscopy-based polyclonal epitope mapping (EMPEM) methodology.

8 May 2022

Scientists explore immunopathology of COVID-19

Researchers explored the interactions between severe acute respiratory syndrome coronavirus 2 and the host in the development of COVID-19.

6 May 2022

Marine bioactive compounds against SARS-CoV-2

A new review paper published in the journal Environmental Science and Pollution Research aimed to determine the possibilities of using biologically active compounds derived from various chemical classes of marine organisms against SARS-CoV-2 infection at various stages of the life cycle of the virus.

6 May 2022

Is type 1 diabetes likely to rise after the COVID pandemic?

A recent article posted to the journal Diabetes/Metabolism Research and Reviews explored the risk of a type 1 diabetes wave after the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.

6 May 2022

miRNAs associated with varying clinical presentations of SARS-CoV-2

A recent article published in the journal iSCIENCE demonstrated different micro ribonucleic acids (miRNAs) linked with various presentations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.

5 May 2022

Results indicate that Omicron infection induces low levels of neutralizing antibodies in immunocompetent individuals

Researchers assessed the induction of variant-specific neutralizing antibodies against the SARS-CoV-2 spike and nucleocapsid proteins of several SARS-CoV-2 strains.

5 May 2022

Free SARS-CoV-2 spike protein fragments may trigger platelet activation and clot formation in COVID-19

In a recent study under review in the Nature Portfolio journal and currently available on the Research Square* preprint server, researchers investigated the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (SP) in the thrombi (or blood clots).

5 May 2022